Logo image of FVE

FIVE STAR SENIOR LIVING INC (FVE) Stock Fundamental Analysis

NASDAQ:FVE - Nasdaq - US33832D1063 - Common Stock

2.94  +0.07 (+2.44%)

Fundamental Rating

1

FVE gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of FVE have multiple concerns. FVE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

FVE had negative earnings in the past year.
FVE Yearly Net Income VS EBIT VS OCF VS FCFFVE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 50M -50M -100M

1.2 Ratios

Industry RankSector Rank
ROA -4.4%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FVE Yearly ROA, ROE, ROICFVE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM 0.52%
PM (TTM) -1.57%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FVE Yearly Profit, Operating, Gross MarginsFVE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 20 40 60 80

2

2. Health

2.1 Basic Checks

FVE has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, FVE has a worse debt to assets ratio.
FVE Yearly Shares OutstandingFVE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 10M 20M 30M
FVE Yearly Total Debt VS Total AssetsFVE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 100M 200M 300M 400M 500M

2.2 Solvency

FVE has an Altman-Z score of 2.16. This is not the best score and indicates that FVE is in the grey zone with still only limited risk for bankruptcy at the moment.
FVE has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACCN/A
WACCN/A
FVE Yearly LT Debt VS Equity VS FCFFVE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 100M -100M 200M

2.3 Liquidity

FVE has a Current Ratio of 1.51. This is a normal value and indicates that FVE is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.51 indicates that FVE should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
FVE Yearly Current Assets VS Current LiabilitesFVE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M 150M 200M 250M

1

3. Growth

3.1 Past

FVE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.90%.
FVE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -15.26%.
FVE shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.15% yearly.
EPS 1Y (TTM)-117.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-283.33%
Revenue 1Y (TTM)-15.26%
Revenue growth 3Y-5.89%
Revenue growth 5Y-3.15%
Sales Q2Q%-23.52%

3.2 Future

The Earnings Per Share is expected to grow by 61.66% on average over the next years. This is a very strong growth
Based on estimates for the next years, FVE will show a decrease in Revenue. The Revenue will decrease by -9.86% on average per year.
EPS Next Y-120%
EPS Next 2Y28.06%
EPS Next 3Y53.83%
EPS Next 5Y61.66%
Revenue Next Year-19.45%
Revenue Next 2Y-18%
Revenue Next 3Y-11.55%
Revenue Next 5Y-9.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
FVE Yearly Revenue VS EstimatesFVE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
FVE Yearly EPS VS EstimatesFVE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 0 2 -2 -4

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FVE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FVE Price Earnings VS Forward Price EarningsFVE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.27
FVE Per share dataFVE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A more expensive valuation may be justified as FVE's earnings are expected to grow with 53.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.06%
EPS Next 3Y53.83%

0

5. Dividend

5.1 Amount

FVE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

FIVE STAR SENIOR LIVING INC

NASDAQ:FVE (1/27/2022, 8:26:29 PM)

2.94

+0.07 (+2.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)02-23 2022-02-23
Inst Owners0%
Inst Owner Change0%
Ins Owners0.72%
Ins Owner Change0%
Market Cap93.36M
Analysts80
Price Target6.63 (125.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B 0.49
P/tB N/A
EV/EBITDA 0.27
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS32.74
BVpS6.04
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.4%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 0.52%
PM (TTM) -1.57%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover2.81
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z 2.16
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-283.33%
EPS Next Y-120%
EPS Next 2Y28.06%
EPS Next 3Y53.83%
EPS Next 5Y61.66%
Revenue 1Y (TTM)-15.26%
Revenue growth 3Y-5.89%
Revenue growth 5Y-3.15%
Sales Q2Q%-23.52%
Revenue Next Year-19.45%
Revenue Next 2Y-18%
Revenue Next 3Y-11.55%
Revenue Next 5Y-9.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A